Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1862649 | 0.98 | CYSLTR2 (0.35) | CYSLTR2CYSLTR1MMP2MMP9MMP8 | |
| SCHEMBL1864907 | 0.98 | CYSLTR2 (0.35) | CYSLTR2CYSLTR1MMP2MMP9MMP8 | |
| SCHEMBL1866608 | 0.98 | CYSLTR2 (0.35) | CYSLTR2CYSLTR1MMP2MMP9MMP8 | |
| SCHEMBL1870722 | 0.98 | CYSLTR2 (0.35) | CYSLTR2CYSLTR1MMP2MMP9MMP8 | |
| SCHEMBL1864023 | 0.98 | CYSLTR2 (0.35) | CYSLTR2CYSLTR1MMP2MMP9MMP8 | |
| SCHEMBL1868845 | 0.94 | TLR8 (0.32) | — | |
| SCHEMBL1868014 | 0.86 | — | — | |
| SCHEMBL2528409 | 0.84 | MAOA (0.31) | — | |
| SCHEMBL11863151 | 0.82 | SIGMAR1 (0.32) | — | |
| SCHEMBL14662476 | 0.81 | RIPK1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296690-B2 | Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2016-03-29 | — | — | US | disclosed |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | METACINE, INC. (KR) | 2014-09-18 | — | — | US | disclosed |
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2014-01-30 | — | — | US | disclosed |
| US-RE43858-E1 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-7935835-B2 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1935879-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | SOST, MYD88, MSR1 | CYSLTR2 2851/4885CYSLTR1 2064/4885MMP2 69/4885 |
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | CD40, LITAF, TNF | CYSLTR2 503/4885CYSLTR1 315/4885MMP2 1796/4885 |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | SOST, MYD88, MSR1 | CYSLTR2 2602/4885CYSLTR1 2032/4885MMP2 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.